Source - SMW
LiDCO, the haemodynamic monitoring company, has welcomed the recent publication of four studies that provide further evidence of the improved outcome benefits derived from the use of LiDCOrapid in high volume general and cardiac surgery.

The Society of Critical Care Medicine journal has published a study evaluating the effects of goal directed therapy using LiDCOrapid in high-risk patients undergoing cardiac surgery. 

The randomised controlled trial involved 126 patients undergoing coronary artery bypass surgery or valve repair. The authors concluded that using LiDCOrapid in these high-risk patients for implementing a goal-directed haemodynamic therapy decreased major complications and also reduced ICU and hospital length of stay. 

The incidence of infection was reduced by 57% and the frequency of low cardiac output syndrome was reduced by 76%. This group stayed in hospital on average three days less than the standard treatment group. 

This is an important study, high-risk cardiac patients require haemodynamic and fluid management both in surgery and also post operatively in the ICU. 

Historically this has only been possible through using a highly invasive pulmonary artery catheter. The LiDCOrapid's minimal and non-invasive nature provides advanced monitoring while avoiding additional invasive catheter insertion.

The World Journal of Surgery recently published a large study examining the influence of an enhanced recovery programme using LiDCOrapid for the fluid management element on the outcomes of upper gastrointestinal cancer surgery in 252 patients. 

Oesophageal cancer surgery is frequently performed in malnourished patients who go on to have a higher incidence of surgical complications that impede recovery.  Both overall length of hospital stay and critical care length of stay were significantly shorter. 

Patients in the enhanced recovery group, where LiDCO technology was used, left hospital on average three days earlier.

Presented at the 11th Annual Academic Surgical Congress in the USA early this year and now having been peer-reviewed and published, a 394 patient study from a major hospital in the USA showed that implementing an enhanced recovery programme for elective abdominal surgery using intraoperative fluid management guided by LiDCOrapid resulted in a statistically significant decrease of two days in mean length of stay. 

In addition, the enhanced recovery group had a zero mortality rate compared to a 2.6% mortality rate in the standard care group. 

The authors also noted that the cost of surgery was less in the enhanced recovery group.   Finally in another of the company's key growth markets, China, a randomised control trial has been published assessing the application of LiDCOrapid for peri-operative fluid therapy for elderly patients undergoing total hip replacement under combined spinal-epidural anaesthesia. Haemodynamic changes are relatively severe in these patients and usu-ally include incidences of low blood pressure and reduced organ perfusion that causes ischemia and complications. 

Clearly an optimal fluid management protocol is crucial for these patients in order to decrease the incidence of hypotension. 

Use of the LiDCOrapid to implement a simple fluid management protocol reduced the number of times pharmaceutical interventions were required while maintaining improved blood pressure, with the result that complications were significantly lower in the LiDCOrapid fluid managed group.

LiDCO chief executive Matt Sassone said: "We continue to see a wealth of clinical evidence demonstrating the benefit of using LiDCO technology in multiple different high-risk surgery procedures from around the world. Having peer-reviewed journal published data substantiating the clinical effectiveness of LiDCOrapid in an expanding number of large volume surgical indications will help us as we seek to further commercialise the business."

Related Charts

LiDCO Group (LID)

+0.38p (+5.36%)
delayed 18:15PM